Our study suggests that the TP73-AS1 could serve as a potential prognostic biomarker and may have a nonnegligible effect on the immune microenvironment composition of glioma, which may provide new insight for the immunological research and treatment of glioma. This evidence concerns the gene TP73 and central nervous system cancer.